. Author manuscript; available in PMC: 2016 Feb 24.

Published in final edited form as: Adv Ther. 2010 Jun 3;27(5):257–284. doi: 10.1007/s12325-010-0028-3

Table 4.

Examples of stroke-preventative effects in selected randomized controlled trials^* of angiotensin II receptor blockers.

Agent	Study	Key findings
Losartan	LIFE	Overall stroke: significant stroke reduction vs. atenolol (25%; P=0.0010),²⁹ with significant reductions in a subset without clinical vascular disease (34%; P<0.001)¹¹¹ and in ischemic (27%; P=0.001), atherothrombotic (27%; P=0.002), and fatal (35%; P=0.032) stroke in a subanalysis of specific subtypes³⁴ Secondary prevention: significant reduction (n=26 vs. n=46; P=0.017) in subtype-focused analysis³⁴

Valsartan	Jikei Heart Study	Overall stroke: significant reduction vs. non-ARB regimens (40%; P=0.028) in stroke or transient ischemic attack in patients with hypertension, coronary heart disease, and/ or heart failure⁵¹
Valsartan	KYOTO HEART Study	Overall stroke: significant reduction vs. non-ARB regimens (45%; P=0.015) in stroke or transient ischemic attack in patients with hypertension at high risk for cardiovascular events⁵²

Candesartan	SCOPE	Overall stroke: significant reduction vs. placebo (28%; P=0.04) in nonfatal stroke in elderly hypertensive patients,⁶⁵ with significant all-stroke reduction in a subset with isolated systolic hypertension⁶⁶
Candesartan	E-COST	Primary prevention: no significant stroke reduction vs. conventional antihypertensive treatment, with a 29% increased risk with candesartan in patients without history of stroke or MI⁶⁴ Secondary prevention: significant stroke reduction for candesartan vs. conventional antihypertensive treatment in patients with past stroke or MI (61%; P<0.01)⁶⁴

Telmisartan	PRoFESS	Secondary prevention: no significant recurrent stroke reduction (primary endpoint) vs. placebo when initiated within 90 days after ischemic stroke⁹³
Telmisartan	TRANSCEND	Overall stroke: no significant stroke reduction vs. placebo in ACEI-intolerant patients with cardiovascular disease or diabetes/end-organ damage⁹²

Eprosartan	MOSES	Secondary prevention: significant reduction vs. nitrendipine (25%; P=0.026) in fatal/ nonfatal cerebrovascular events¹⁰⁴

ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin II receptor blockers; MI=myocardial infarction.

In which the overall study population included >100 patients.